水野 隆一

Medicine & Life Sciences

1. Renal Cell Carcinoma 100%
2. Prostatic Neoplasms 32%
3. Neoplasms 28%
4. Urinary Bladder Neoplasms 26%
5. Carcinoma 26%
6. Prostatectomy 26%
7. Recurrence 25%
8. Nephrectomy 18%
9. Survival 18%
10. Prostate-Specific Antigen 18%
11. Nephroureterectomy 18%
12. Therapeutics 15%
13. Kidney 14%
14. Castration 14%
15. Brachytherapy 13%
16. pembrolizumab 12%
17. Neoplasm Metastasis 12%
18. Prostate 12%
19. Sunitinib 11%
20. Urinary Bladder 10%
21. dehydroxymethylepoxyquinomicin 9%
22. Platinum 9%
23. Docetaxel 9%
24. Androgens 9%
25. Biomarkers 8%
26. Progression-Free Survival 8%
27. Drug Therapy 8%
28. Survival Rate 7%
29. Bacillus 7%
30. C-Reactive Protein 7%
31. Seeds 7%
32. Multivariate Analysis 7%
33. Tomography 7%
34. Adrenalectomy 7%
35. Salvage Therapy 6%
36. Neoplasm Grading 6%
37. Vascular Endothelial Growth Factor A 6%
38. Clear-cell metastatic renal cell carcinoma 6%
39. Epithelial-Mesenchymal Transition 6%
40. Nivolumab 6%
41. Axitinib 5%
42. Angiomyolipoma 5%